Frontlight ResearchEarly access
Spinal muscular atrophy trials in Norway
1 trial · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3WithdrawnA Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
- Where
- Oslo
- Age
- 0 days to 7 months
- People
- 42 worldwide
- Run by
- Biogen
See details and how to joinNCT07444450 · EU 2025-523857-32-00